triphosphoric acid has been researched along with Hepatitis C in 3 studies
triphosphoric acid: used as water softener, peptizing agent, emulsifier & dispersing agent; ingredient of cleansers; meat preservative; RN given refers to parent cpd; structure
Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The application of a phosphoramidate prodrug approach to 2'-C-methylcytidine (NM107), the first nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, is reported." | 7.75 | Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection. ( Attenni, B; Di Marco, A; Donghi, M; Fiore, F; Gardelli, C; Gennari, N; Giuliano, C; Harper, S; Laufer, R; Leone, JF; MacCoss, M; Marcucci, I; Meppen, M; Narjes, F; Olsen, DB; Pacini, B; Pucci, V; Rowley, M, 2009) |
| "Ribavirin (RBV) is an antiviral drug that is part of the current standard therapy for chronic hepatitis C (CHC)." | 3.91 | Tolerability of Erythrocyte Ribavirin Triphosphate Concentrations Depends on the ITPA Genotype. ( Inoue, A; Komiyama, T; Matsumura, H; Mizunuma, T; Otori, K; Tanaka, Y; Yokomori, H, 2019) |
| "The application of a phosphoramidate prodrug approach to 2'-C-methylcytidine (NM107), the first nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, is reported." | 3.75 | Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection. ( Attenni, B; Di Marco, A; Donghi, M; Fiore, F; Gardelli, C; Gennari, N; Giuliano, C; Harper, S; Laufer, R; Leone, JF; MacCoss, M; Marcucci, I; Meppen, M; Narjes, F; Olsen, DB; Pacini, B; Pucci, V; Rowley, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Brooks, KM | 1 |
| Castillo-Mancilla, JR | 1 |
| Morrow, M | 1 |
| Mawhinney, S | 1 |
| Rowan, SE | 1 |
| Wyles, D | 1 |
| Blum, J | 1 |
| Huntley, R | 1 |
| Salah, L | 1 |
| Tehrani, A | 1 |
| Jimmerson, LC | 1 |
| Roon, L | 1 |
| Bushman, LR | 1 |
| Anderson, PL | 1 |
| Kiser, JJ | 1 |
| Tanaka, Y | 1 |
| Inoue, A | 1 |
| Mizunuma, T | 1 |
| Matsumura, H | 1 |
| Yokomori, H | 1 |
| Komiyama, T | 1 |
| Otori, K | 1 |
| Gardelli, C | 1 |
| Attenni, B | 1 |
| Donghi, M | 1 |
| Meppen, M | 1 |
| Pacini, B | 1 |
| Harper, S | 1 |
| Di Marco, A | 1 |
| Fiore, F | 1 |
| Giuliano, C | 1 |
| Pucci, V | 1 |
| Laufer, R | 1 |
| Gennari, N | 1 |
| Marcucci, I | 1 |
| Leone, JF | 1 |
| Olsen, DB | 1 |
| MacCoss, M | 1 |
| Rowley, M | 1 |
| Narjes, F | 1 |
1 trial available for triphosphoric acid and Hepatitis C
| Article | Year |
|---|---|
Predictors of 007 triphosphate concentrations in dried blood spots in persons with hepatitis C and active drug or alcohol use.
Topics: Dried Blood Spot Testing; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Polyphosph | 2022 |
2 other studies available for triphosphoric acid and Hepatitis C
| Article | Year |
|---|---|
Tolerability of Erythrocyte Ribavirin Triphosphate Concentrations Depends on the ITPA Genotype.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Erythrocytes; Female; Genotype; Hepa | 2019 |
Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection.
Topics: Amides; Animals; Antiviral Agents; Cell Line; Cytidine; Hepacivirus; Hepatitis C; Hepatocytes; Human | 2009 |